CPACS Trial Opens for RC220 Patient Enrolment in Korea
Filed with ASX · · 6 pages · English
Story so far
Earlier from Racura Oncology
- Corporate Governance Statement
- Appendix 4G
- Appendix 4E & Annual Report
- First HARNESS-1 Patient Safely Treated with RC220
- Racure Oncology Techknow Invest Presentation
Later from Racura Oncology
- Notification regarding unquoted securities - RAC
- Racura Oncology Adelaide Investor Briefing
- RC220 MYC-silencing data to be presented FCS 26 conference
- Appendix 3Y - Dr Daniel Tillett
- Date of AGM & Closing Date for Director Nominations
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology